Dignitana (DIGN.ST) Stock Analysis & AI Equity Report
Dignitana (DIGN.ST) overview
Dignitana (DIGN.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, Dignitana reported revenue of SEK 89.8m and operating profit of SEK -18.3m; the year-end share price was 0.96 SEK and market capitalisation was SEK 74.3m. Dignitana is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Dignitana's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-09-05. Data will be refreshed during report generation.
About Dignitana
Dignitana AB is a Swedish medical technology company that develops, manufactures and markets the DigniCap scalp cooling system, a patented medical device used during chemotherapy to reduce hair loss and support patient comfort. The company serves hospitals and clinics through product sales, support and related services, and says it became part of the Paxman Group in June 2025.
Generate the Dignitana report
Dignitana is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Dignitana and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.